GlassScriptPhysician profile
David Michael Kinker
NPI 1588346332
$3,450.96
in general payments reported to CMS, 2019-2025
25 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $912 · 2024: $2,095 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.97 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $529.38 | 2023-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $334.79 | 2023-2025 | |
| United Therapeutics Corporation | $329.12 | 2024-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $306.62 | 2023-2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $290.49 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.76 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $216.25 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $195.97 | 2023-2025 | |
| Esperion Therapeutics, INC. | $177.46 | 2023-2024 | Nexletol |
| Amgen INC. | $151.47 | 2023-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $99.47 | 2023-2024 | |
| Abiomed | $98.55 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $90.76 | 2023-2024 | Farxiga |
| Boston Scientific Corporation | $73.86 | 2024 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $59.48 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $39.43 | 2025 | Amvuttra |
| Daiichi Sankyo INC. | $39.17 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $34.28 | 2025 | Camzyos, Eliquis |
| Philips North America LLC | $29.89 | 2023 | |
| Inspire Medical Systems, INC. | $28.94 | 2025 | Inspire |
| Cvrx, INC. | $25.93 | 2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $21.93 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.64 | 2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $17.84 | 2024 | |
| Irhythm Technologies, INC. | $13.48 | 2024 | Zio Monitor, Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.